Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...